A Randomized, Blinded Phase I./II Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant
Latest Information Update: 19 May 2025
At a glance
- Drugs Adjuvants (Primary) ; Influenza virus split vaccine Chongqing Zhifei Biological Products (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Anhui Zhifei Longcom Biopharmaceutical
Most Recent Events
- 11 May 2025 Status changed from not yet recruiting to recruiting.
- 21 Feb 2025 New trial record